Sandra Boehncke1, Hanns Ackermann, Klaus Badenhoop, Matthias Sitzer. 1. Department of Internal Medicine 1, Division of Endocrinology, Diabetes and Metabolism, Stroke Unit, J.W. Goethe University, Frankfurt/M., Germany. Sandra.Boehncke@kgu.de
Abstract
BACKGROUND: Pituitary dysfunction is a known complication of traumatic brain injury and subarachnoidal hemorrhage but there are few data about pituitary dysfunction as a complication of ischemic stroke. METHODS: We prospectively studied patients 66-274 days after an ischemic stroke, evaluating the prevalence of pituitary dysfunction (by combined releasing hormone testing: GHRH, CRH), stroke severity, outcome and incidence of anxiety and depression. RESULTS: Thirty-two patients (82%) presented with some degree of pituitary dysfunction with predominantly impaired growth hormone response (79.5%) and secondary adrenal failure (14.6%). Abnormal anxiety and/or depression was found in 28.3 and 32.7% of the patients. NIHSS (National Institute of Health Stroke Scale) varied between 1 and 15. Improvement in neurological deficit (ΔNIHSS) correlated significantly with NIHSS at baseline (p < 0.001) but not with pituitary function. CONCLUSIONS: Patients with ischemic stroke may suffer from pituitary dysfunction with predominantly impaired growth hormone response and secondary adrenal failure. We suggest that patients who suffer from stroke should undergo pituitary testing.
BACKGROUND:Pituitary dysfunction is a known complication of traumatic brain injury and subarachnoidal hemorrhage but there are few data about pituitary dysfunction as a complication of ischemic stroke. METHODS: We prospectively studied patients 66-274 days after an ischemic stroke, evaluating the prevalence of pituitary dysfunction (by combined releasing hormone testing: GHRH, CRH), stroke severity, outcome and incidence of anxiety and depression. RESULTS: Thirty-two patients (82%) presented with some degree of pituitary dysfunction with predominantly impaired growth hormone response (79.5%) and secondary adrenal failure (14.6%). Abnormal anxiety and/or depression was found in 28.3 and 32.7% of the patients. NIHSS (National Institute of Health Stroke Scale) varied between 1 and 15. Improvement in neurological deficit (ΔNIHSS) correlated significantly with NIHSS at baseline (p < 0.001) but not with pituitary function. CONCLUSIONS:Patients with ischemic stroke may suffer from pituitary dysfunction with predominantly impaired growth hormone response and secondary adrenal failure. We suggest that patients who suffer from stroke should undergo pituitary testing.
Authors: F Tanriverdi; A Agha; G Aimaretti; F F Casanueva; F Kelestimur; M Klose; B E Masel; A M Pereira; V Popovic; H J Schneider Journal: J Endocrinol Invest Date: 2011-06-21 Impact factor: 4.256
Authors: Fei Wang; Ming-Ying Luo; Lei Zhou; Li Yang; Giuseppe Lanzino; Heng-Jui Chang; George C Wellman Journal: J Neuroimmune Pharmacol Date: 2020-07-03 Impact factor: 4.147
Authors: Sonia Sanchez-Bezanilla; N David Åberg; Patricia Crock; Frederick R Walker; Michael Nilsson; Jörgen Isgaard; Lin Kooi Ong Journal: Int J Mol Sci Date: 2020-01-17 Impact factor: 5.923